nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Methimazole—Graves' disease	0.464	0.632	CbGbCtD
Bexarotene—CYP3A4—Methimazole—Graves' disease	0.27	0.368	CbGbCtD
Bexarotene—Neuritis—Methimazole—Graves' disease	0.0156	0.0635	CcSEcCtD
Bexarotene—Neuritis—Propylthiouracil—Graves' disease	0.0133	0.054	CcSEcCtD
Bexarotene—Skin ulcer—Propylthiouracil—Graves' disease	0.0127	0.0518	CcSEcCtD
Bexarotene—Liver injury—Propylthiouracil—Graves' disease	0.0118	0.0479	CcSEcCtD
Bexarotene—Lymphadenopathy—Methimazole—Graves' disease	0.00992	0.0403	CcSEcCtD
Bexarotene—RXRB—Vitamin D Metabolism—GC—Graves' disease	0.00981	0.498	CbGpPWpGaD
Bexarotene—Lymphadenopathy—Propylthiouracil—Graves' disease	0.00843	0.0343	CcSEcCtD
Bexarotene—Hepatic failure—Propylthiouracil—Graves' disease	0.00801	0.0325	CcSEcCtD
Bexarotene—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00763	0.031	CcSEcCtD
Bexarotene—Neuropathy peripheral—Methimazole—Graves' disease	0.00639	0.026	CcSEcCtD
Bexarotene—Jaundice—Methimazole—Graves' disease	0.00636	0.0258	CcSEcCtD
Bexarotene—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00544	0.0221	CcSEcCtD
Bexarotene—Jaundice—Propylthiouracil—Graves' disease	0.0054	0.022	CcSEcCtD
Bexarotene—Alopecia—Methimazole—Graves' disease	0.00517	0.021	CcSEcCtD
Bexarotene—RXRA—Vitamin D Metabolism—GC—Graves' disease	0.00511	0.259	CbGpPWpGaD
Bexarotene—Haemoglobin—Propylthiouracil—Graves' disease	0.005	0.0203	CcSEcCtD
Bexarotene—Haemorrhage—Propylthiouracil—Graves' disease	0.00498	0.0202	CcSEcCtD
Bexarotene—Vertigo—Methimazole—Graves' disease	0.00458	0.0186	CcSEcCtD
Bexarotene—Leukopenia—Methimazole—Graves' disease	0.00456	0.0185	CcSEcCtD
Bexarotene—Alopecia—Propylthiouracil—Graves' disease	0.0044	0.0179	CcSEcCtD
Bexarotene—Myalgia—Methimazole—Graves' disease	0.00434	0.0176	CcSEcCtD
Bexarotene—Arthralgia—Methimazole—Graves' disease	0.00434	0.0176	CcSEcCtD
Bexarotene—Dysgeusia—Propylthiouracil—Graves' disease	0.00424	0.0172	CcSEcCtD
Bexarotene—Oedema—Methimazole—Graves' disease	0.00416	0.0169	CcSEcCtD
Bexarotene—Thrombocytopenia—Methimazole—Graves' disease	0.00407	0.0166	CcSEcCtD
Bexarotene—Vertigo—Propylthiouracil—Graves' disease	0.00389	0.0158	CcSEcCtD
Bexarotene—Leukopenia—Propylthiouracil—Graves' disease	0.00388	0.0158	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00379	0.0154	CcSEcCtD
Bexarotene—Paraesthesia—Methimazole—Graves' disease	0.00373	0.0152	CcSEcCtD
Bexarotene—Somnolence—Methimazole—Graves' disease	0.0037	0.015	CcSEcCtD
Bexarotene—Myalgia—Propylthiouracil—Graves' disease	0.00369	0.015	CcSEcCtD
Bexarotene—Arthralgia—Propylthiouracil—Graves' disease	0.00369	0.015	CcSEcCtD
Bexarotene—Dyspepsia—Methimazole—Graves' disease	0.00366	0.0149	CcSEcCtD
Bexarotene—Oedema—Propylthiouracil—Graves' disease	0.00354	0.0144	CcSEcCtD
Bexarotene—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00346	0.0141	CcSEcCtD
Bexarotene—Body temperature increased—Methimazole—Graves' disease	0.00329	0.0134	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00322	0.0131	CcSEcCtD
Bexarotene—Paraesthesia—Propylthiouracil—Graves' disease	0.00318	0.0129	CcSEcCtD
Bexarotene—Somnolence—Propylthiouracil—Graves' disease	0.00314	0.0128	CcSEcCtD
Bexarotene—Dyspepsia—Propylthiouracil—Graves' disease	0.00311	0.0127	CcSEcCtD
Bexarotene—Pruritus—Methimazole—Graves' disease	0.00294	0.012	CcSEcCtD
Bexarotene—Body temperature increased—Propylthiouracil—Graves' disease	0.0028	0.0114	CcSEcCtD
Bexarotene—Vomiting—Methimazole—Graves' disease	0.00264	0.0107	CcSEcCtD
Bexarotene—Rash—Methimazole—Graves' disease	0.00262	0.0107	CcSEcCtD
Bexarotene—Dermatitis—Methimazole—Graves' disease	0.00262	0.0106	CcSEcCtD
Bexarotene—Headache—Methimazole—Graves' disease	0.00261	0.0106	CcSEcCtD
Bexarotene—Pruritus—Propylthiouracil—Graves' disease	0.0025	0.0102	CcSEcCtD
Bexarotene—Nausea—Methimazole—Graves' disease	0.00247	0.01	CcSEcCtD
Bexarotene—Vomiting—Propylthiouracil—Graves' disease	0.00225	0.00914	CcSEcCtD
Bexarotene—Rash—Propylthiouracil—Graves' disease	0.00223	0.00906	CcSEcCtD
Bexarotene—Dermatitis—Propylthiouracil—Graves' disease	0.00223	0.00905	CcSEcCtD
Bexarotene—Headache—Propylthiouracil—Graves' disease	0.00222	0.00901	CcSEcCtD
Bexarotene—Nausea—Propylthiouracil—Graves' disease	0.0021	0.00854	CcSEcCtD
Bexarotene—RXRA—Orphan transporters—GABRA3—Graves' disease	0.00073	0.037	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.000643	0.0327	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.000605	0.0307	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—FAS—Graves' disease	0.000418	0.0212	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—TNF—Graves' disease	0.00036	0.0183	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.000315	0.016	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—FAS—Graves' disease	0.000205	0.0104	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000202	0.0102	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000178	0.00904	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—TNF—Graves' disease	0.000178	0.00901	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000156	0.00793	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000151	0.00764	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—Graves' disease	0.000132	0.00671	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GC—Graves' disease	8.98e-05	0.00456	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—TNF—Graves' disease	8.7e-05	0.00441	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—GC—Graves' disease	7.53e-05	0.00382	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—B3GNT2—Graves' disease	6.81e-05	0.00345	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	6.4e-05	0.00325	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GC—Graves' disease	3.35e-05	0.0017	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TNF—Graves' disease	2.99e-05	0.00152	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—B3GNT2—Graves' disease	2.54e-05	0.00129	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GC—Graves' disease	2.21e-05	0.00112	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—B3GNT2—Graves' disease	1.68e-05	0.00085	CbGpPWpGaD
